GWMIA
NBIX icon

Global Wealth Management Investment Advisory’s Neurocrine Biosciences NBIX Stock Holding History

Global Wealth Management Investment Advisory’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-50
Closed -$6K – 558
2020
Q2 		$6K Buy
+50
New +$5.53K ﹤0.01% 406
2020
Q1 		– Sell
-75
Closed -$8K – 637
2019
Q4 		$8K Buy
+75
New +$7.85K ﹤0.01% 383

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Global Wealth Management Investment Advisory's NBIX Position: Q3 2020 in Review

Global Wealth Management Investment Advisory sold out of Neurocrine Biosciences (NBIX) in Q3 2020, closing a stake of 50 shares — an estimated $6K sold.

Global Wealth Management Investment Advisory first reported a position in NBIX in Q4 2019 and held it in 2 quarters. The position peaked at $8K in Q4 2019. 419 funds tracked by Wall St. Rank hold NBIX as of Q3 2020.

  • Global Wealth Management Investment Advisory reported no remaining Neurocrine Biosciences position as of Q3 2020 after selling out during the quarter.
  • Global Wealth Management Investment Advisory sold 50 Neurocrine Biosciences shares in Q3 2020, an estimated $6K.
  • Global Wealth Management Investment Advisory first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 2 quarters.
  • Global Wealth Management Investment Advisory's Neurocrine Biosciences position peaked at $8K in Q4 2019.
  • 419 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2020.

Based on Global Wealth Management Investment Advisory's 13F filing for Q3 2020, filed 16 Nov 2020.